The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies.
 
Neelima Vidula
No Relationships to Disclose
 
Andrei Goga
No Relationships to Disclose
 
Jimmy Hwang
No Relationships to Disclose
 
Minetta C. Liu
Research Funding - Eisai (Inst); GRAIL (Inst); Janssen Diagnostics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Agena Bioscience; Celgene; Cynvenio Biosystems; GRAIL; Menarini Silicon Biosystems; Merck
 
Ben Ho Park
Leadership - Loxo
Stock and Other Ownership Interests - Loxo
Consulting or Advisory Role - Foundation Medicine; Horizon Discovery; Loxo
Research Funding - Foundation Medicine
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; Celgene; Genentech/Roche; Merck; Pfizer; Puma Biotechnology; Syndax
Research Funding - Celgene; Corcept Therapeutics; Merck
Other Relationship - G1 Therapeutics
 
Paula Raffin Pohlmann
Leadership - Immunonet BioSciences
Stock and Other Ownership Interests - Immunonet BioSciences
Consulting or Advisory Role - HERON; Immunonet BioSciences; OncoPlex Diagnostics; Personalized Cancer Therapy; Pfizer
Research Funding - Advanced Cancer Therapeutics (Inst); Caris Centers of Excellence (Inst); Caris Centers of Excellence (Inst); Cascadian Therapeutics (Inst); Fabre-Kramer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - IMMUNOLOGICAL COMPOSITIONS AS CANCER BIOMARKERS AND/OR THERAPEUTICS; U.S. Patent and Trademark Office No. US 20120201820. Invention title: Immunological Compositions as Cancer Therapeutics.
 
Anna Maria Storniolo
No Relationships to Disclose
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Bayer; bioTheranostics; Celgene; Genentech/Roche; Genomic Health; Lilly; NanoString Technologies; Novartis; Pfizer; Puma Biotechnology
 
Vandana Gupta Abramson
Consulting or Advisory Role - Novartis
Research Funding - Astellas Pharma; Genentech/Roche
 
Hope S. Rugo
Honoraria - Genomic Health
Consulting or Advisory Role - Amgen
Speakers' Bureau - Genomic Health
Research Funding - Eisai (Inst); Genentech (Inst); GTx (Inst); Immunomedics (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech